Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/24254

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24254

题名:	Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
作者:	Sheikh, S;Wei, CC;Tegzova, D;Stohl, W;de Toledo, RA;Mucenic, T;Banfi, MA;Maksimowicz-McKinnon, K;Abud-Mendoza, C;Navarra, S;Garcia, M;Garcia-De La Torre, I;Kurrasch, R;Fernandes, S;Harris, J;Muzaffar, S;Fox, NL;Liu, A;Quasny, H;Roth, D
日期:	2021
上传时间:	2022-08-05T10:45:34Z (UTC)
出版者:	WILEY
ISSN:	2326-5191
URI:	https://www.webofscience.com/wos/woscc/full-record/WOS:000744545205084 https://ir.csmu.edu.tw:8080/handle/310902500/24254
關聯:	ARTHRITIS & RHEUMATOLOGY ,2021 ,v73 ,p2699-2699
显示于类别:	[中山醫學大學研究成果] 其他文獻

文件中的档案:

没有与此文件相关的档案.

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章